SI3134430T1 - ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS - Google Patents
ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS Download PDFInfo
- Publication number
- SI3134430T1 SI3134430T1 SI201530223T SI201530223T SI3134430T1 SI 3134430 T1 SI3134430 T1 SI 3134430T1 SI 201530223 T SI201530223 T SI 201530223T SI 201530223 T SI201530223 T SI 201530223T SI 3134430 T1 SI3134430 T1 SI 3134430T1
- Authority
- SI
- Slovenia
- Prior art keywords
- trail receptor
- receptor protein
- trail
- protein agonist
- diseases
- Prior art date
Links
- 229940123369 TRAIL receptor agonist Drugs 0.000 title claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 12
- 201000010099 disease Diseases 0.000 claims abstract 8
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims abstract 4
- 108700012411 TNFSF10 Proteins 0.000 claims abstract 4
- 208000035475 disorder Diseases 0.000 claims abstract 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 11
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 11
- 229940076376 protein agonist Drugs 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 229940043131 pyroglutamate Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 | |
| EP15721089.9A EP3134430B1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
| PCT/US2015/027270 WO2015164588A1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3134430T1 true SI3134430T1 (en) | 2018-05-31 |
Family
ID=53055121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530223T SI3134430T1 (en) | 2014-04-23 | 2015-04-23 | ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170138585A (ko) | 2015-05-04 | 2017-12-15 | 아포게닉스 아게 | 단일-쇄 cd40-수용체 작용제 단백질 |
| WO2017068192A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
| WO2017068185A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain gitr-receptor agonist proteins |
| CN108699129A (zh) * | 2015-10-23 | 2018-10-23 | 阿珀吉科吉尼科斯股份公司 | 单链light受体激动剂蛋白 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| US10821160B2 (en) | 2016-03-01 | 2020-11-03 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability |
| MX2018011219A (es) * | 2016-03-16 | 2019-01-10 | Merrimack Pharmaceuticals Inc | Trail diseñado por ingenieria para terapia de cancer. |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109641033A (zh) * | 2016-06-13 | 2019-04-16 | 梅里麦克制药股份有限公司 | 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| JP7744621B2 (ja) * | 2017-08-11 | 2025-09-26 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法 |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| WO2019178433A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
| WO2021229103A2 (en) | 2020-05-15 | 2021-11-18 | Apogenix Ag | Multi-specific immune modulators |
| EP4346885A1 (en) | 2021-05-28 | 2024-04-10 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR025984A1 (es) | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| HU230603B1 (hu) | 2000-12-07 | 2017-03-28 | Eli Lilly And Company | GLP1 fúziós fehérjék |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538088B2 (en) | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| ES2333358T3 (es) | 2005-04-15 | 2010-02-19 | Rappaport Family Institute For Research In The Medical Sciences | Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2. |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| EP2484691B1 (en) | 2007-07-10 | 2016-01-13 | Apogenix GmbH | TNF superfamily collectin fusion proteins |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8450460B2 (en) * | 2008-07-21 | 2013-05-28 | Apogenix Gmbh | Single-chain TNFSF fusion polypeptides |
| MX2011002759A (es) | 2008-09-22 | 2011-07-28 | Amgen Inc | Metodo de tratamiento. |
| WO2010042890A2 (en) * | 2008-10-10 | 2010-04-15 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| EP2829550B1 (en) | 2009-01-09 | 2016-11-16 | Apogenix AG | Fusion proteins forming trimers |
| WO2010085682A2 (en) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| JP2013514795A (ja) * | 2009-12-22 | 2013-05-02 | ノバルティス アーゲー | 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質 |
| MX341119B (es) | 2010-04-13 | 2016-08-09 | Medimmune Llc | Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). |
| US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
| ES2924109T3 (es) | 2012-07-18 | 2022-10-04 | Apogenix Ag | Composición que comprende una mezcla de isoformas de CD95-Fc |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079A1/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3134430T1 (en) | ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS | |
| JP2017513503A5 (enExample) | ||
| US10793616B2 (en) | Single-chain CD40-receptor agonist proteins | |
| CU24314B1 (es) | Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos | |
| PE20121539A1 (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion | |
| JP2013107899A5 (enExample) | ||
| PH12019500853A1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| HRP20241258T1 (hr) | Interleukin-2/interleukin-2 receptor alfa fuzijski proteini i postupci upotrebe | |
| MX2017004947A (es) | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| SG10201809779RA (en) | Site-specific antibody-drug conjugation through glycoengineering | |
| JP2014510519A5 (enExample) | ||
| MY172997A (en) | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| HRP20181055T1 (hr) | Antagonisti kv1.3 i postupci upotrebe | |
| HRP20191511T1 (hr) | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba | |
| WO2011012609A3 (en) | Anti - tgf - beta receptor type ii single domain antibodies | |
| JP2018533948A5 (enExample) | ||
| RU2017106743A (ru) | НОВОЕ АНТИТЕЛО ПРОТИВ Igβ ЧЕЛОВЕКА | |
| JP2017538443A5 (enExample) | ||
| NZ707850A (en) | Polypeptides derived from tgfβ and uses thereof | |
| JP2017500030A5 (enExample) | ||
| WO2015134833A3 (en) | Therapeutic proteins for treating cancers and methods for using such proteins | |
| DAI et al. | Screening and identification of polypeptides targeting hepatitis B virus HBP-TP protein | |
| EA202092106A3 (ru) | Модифицированные полипептиды fgf-21 и их применение |